PDEF downregulates stathmin expression in prostate cancer

  • Authors:
    • Yamini Sabherwal
    • Nitin Mahajan
    • Donald L. Helseth
    • Mayumi Gassmann
    • Heidi Shi
    • Ming Zhang
  • View Affiliations

  • Published online on: February 29, 2012     https://doi.org/10.3892/ijo.2012.1392
  • Pages: 1889-1899
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The Ets proteins are a family of transcription factors characterized by an evolutionarily conserved DNA binding domain that controls key cellular processes. Prostate-derived Ets transcription factor (PDEF), a member of the Ets family, is reported to be present in tissues with high epithelial content, notably breast and prostate. However, the role of PDEF in cancer development is not fully understood. To gain insight into the molecular mechanisms associated with prostate cancer progression, we employed iTRAQ labeling followed by mass spectrometric (MS) analysis to identify candidate proteins that are differentially expressed in prostate cancer cells with or without PDEF. To this end, we overexpressed PDEF in PC3 human prostate cells using a tetracycline inducible system (Tet-On). Many differentially expressed proteins which play important roles in various cellular and biological processes were identified. Among them, stathmin (STMN), which is a microtubule (MT)-destabilizing protein, was found to be downregulated in multiple analyses. We demonstrated that re-expression of STMN reversed the antitumor properties of PDEF in PDEF-overexpressing PC3 cells. Using in vitro functional assays, we showed that STMN overexpression counteracted PDEF's effects against cell proliferation, colony formation and tumor migration. Similar results were further confirmed with the prostate cancer cell line CWR22rv1. In conclusion, many differentially expressed proteins were identified and STMN was found to be downregulated by PDEF. These results suggest that PDEF may inhibit prostate cancer progression by transcriptional downregulation of oncogenic STMN expression. Analyzing the association among differentially expressed proteins may provide a basis to better understand the molecular mechanisms underlying the process of cancer progression and development and further aid in designing therapeutics in the future.

Related Articles

Journal Cover

June 2012
Volume 40 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sabherwal Y, Mahajan N, Helseth DL, Gassmann M, Shi H and Zhang M: PDEF downregulates stathmin expression in prostate cancer. Int J Oncol 40: 1889-1899, 2012
APA
Sabherwal, Y., Mahajan, N., Helseth, D.L., Gassmann, M., Shi, H., & Zhang, M. (2012). PDEF downregulates stathmin expression in prostate cancer. International Journal of Oncology, 40, 1889-1899. https://doi.org/10.3892/ijo.2012.1392
MLA
Sabherwal, Y., Mahajan, N., Helseth, D. L., Gassmann, M., Shi, H., Zhang, M."PDEF downregulates stathmin expression in prostate cancer". International Journal of Oncology 40.6 (2012): 1889-1899.
Chicago
Sabherwal, Y., Mahajan, N., Helseth, D. L., Gassmann, M., Shi, H., Zhang, M."PDEF downregulates stathmin expression in prostate cancer". International Journal of Oncology 40, no. 6 (2012): 1889-1899. https://doi.org/10.3892/ijo.2012.1392